

Jan-22-07 15:33

From:Hogan & Hartson LLP Los Angeles, Ca.

+213 337 6701

T-902 P.001/013 F-799

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

**HOGAN &
HARTSON**

Hogan & Hartson LLP
1999 Avenue of the Stars
Suite 1400
Los Angeles, CA 90067
+1.310.785.4600 Tel
+1.310.785.4601 Fax

www.hhlaw.com

TELECOPY/FACSIMILE

To:	Company:	Fax Number:	Tel Number:
Examiner: Terra C. Gibbs	U.S. Patent and Trademark Office	571 - 273 - 8300 Art Unit 1635	

From: Lawrence J. McClure
Date: January 22, 2007
Time:
Total number of pages incl. cover page: 13

For internal purposes only: Please Return Fax to Nancy
Nolen
Client number: 89188.0050
Attorney billing number: 1966
Confirmation number: 310-785-4600


The attached information is CONFIDENTIAL and is intended only for the use of the addressee(s) named above. If the reader of this message is not the intended recipient(s) or the employee or agent responsible for delivering the message to the intended recipient(s), please note that any dissemination, distribution or copying of this communication is strictly prohibited. Anyone who receives this communication in error should notify us immediately by telephone and return the original message to us at the above address via the U.S. Mail

MESSAGE:

RE: U.S. Patent Application Serial No.: 10/663,875, Our Ref. 89188.0050
I hereby certify that the following documents:

Amendment Transmittal Letter (2)
 Amendment and Response to Restriction Requirement

January 22, 2007
Date of Deposit


Nancy Nolen

are being facsimiled to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, for filing in the above-identified application.

Baltimore Boling Berlin Boulder Brussels Budapest Caracas Colorado Springs Denver Geneva Hong Kong London Los Angeles
Miami Moscow Munich New York Northern Virginia Paris Shanghai Tokyo Warsaw Washington, D.C.

WLA - 9188.00050 - 335803 v1

FORM PT(O)-1083

89188.0050

Patent Application No. 10/663,875

RECEIVED
CENTRAL FAX CENTER

JAN 22 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shi-Lung LIN et al.

Serial No: 10/663,875

Filed: September 16, 2003

For: RNA-MEDIATED GENE MODULATION

Art Unit: 1635
Examiner: Terra C. Gibbs

I hereby certify that this correspondence
is being transmitted via facsimile to
(571) 273-8300:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

January 22, 2007
Date of Deposit
Nancy Nolen
Name
Signature 01/22/07
Date

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an amendment in the above-identified application, and:

Amendment and Response to Restriction Requirement
 No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA*	LG/SM \$ ENTITY FEE		ADD'L FEE DUE
TOTAL CLAIMS FEE	10	-	57	--	LG=\$50 SM=\$25	\$0	\$ 0
INDEPENDENT CLAIMS FEE	3	-	9	***	LG=\$100 SM=\$200	\$0	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS							
LARGE ENTITY FEE = \$360 SMALL ENTITY FEE = \$180							
TOTAL \$ 0							

Independent Claims: 1, 7, 8

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

A check in the amount of \$____ to cover the additional claims fee is enclosed. A copy of this sheet is enclosed.

A check in the amount of \$____ to cover the extension fee is enclosed. A copy of this sheet is enclosed.


The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. A copy of this sheet is enclosed.

Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims

Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,

HOGAN & HARTSON L.L.P.

By: Lawrence J. McCleure
Registration No. 44,228

Date: January 22, 2007

1999 Avenue of the Stars, Suite 1400
Los Angeles, California 9067
Telephone: 310-785-4600
Facsimile: 310-785-4601

FORM PT(O)-1083

89188.0050
Patent Application No. 10/663,875RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shi-Lung LIN et al.

Serial No. 10/663,875

Filed: September 16, 2003

For: RNA-MEDIATED GENE MODULATION

Art Unit: 1635
Examiner: Terra C. Gibbs

JAN 22 2007

I hereby certify that this correspondence
is being transmitted via facsimile to
(571) 273-8300:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on

January 22, 2007
Date of Deposit
Nancy Nolen
Name
Signature *Nancy Nolen* 01/22/07
Date

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an amendment in the above-identified application, and:

Amendment and Response to Restriction Requirement
 No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA*	LG/SM \$ ENTITY FEE		ADD'L FEE DUE
TOTAL CLAIMS FEE	10	-	57	0	LG=\$80 SM=\$25	\$0	\$ 0
INDEPENDENT CLAIM FEE	3	-	8	0	LG=\$100 SM=\$200	\$0	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS							
LARGE ENTITY FEE = \$360 SMALL ENTITY FEE = \$180							
Independent Claims: 1, 7, 8							
TOTAL \$ 0							

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the Highest Number Previously Paid For IN THIS SPACE is less than 20, write "20" in this space.
 *** If the Highest Number Previously Paid For IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

A check in the amount of \$____ to cover the additional claims fee is enclosed. A copy of this sheet is enclosed.

A check in the amount of \$____ to cover the extension fee is enclosed. A copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 50-1314. A copy of this sheet is enclosed.

Any filing fees under 37 C.F.R. § 1.18 for the presentation of extra claims

Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,

HOGAN & HARTSON L.L.P.

By:

Lawrence J. McClure
Lawrence J. McClure
Registration No. 44,228

Date: January 22, 2007

1999 Avenue of the Stars, Suite 1400
Los Angeles, California 9067
Telephone: 310-785-4600
Facsimile: 310-785-4601

Application Serial No. 10/663,875

PATENT
89188.0050RECEIVED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
CENTRAL FAX CENTER

JAN 22 2007

In re application of:

Shi Lung LIN and Shao-Yao YING

Serial No: 10/663,875

Filed: September 16, 2003

For: RNA-MEDIATED GENE MODULATION

Art Unit: 1635

Examiner: Gibbs, Terra C.

**AMENDMENT AND RESPONSE
TO RESTRICTION REQUIREMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice of Non-Responsive Amendment dated December 20, 2006, Applicants submit this paper in substitute for the Amendment and Response to Restriction Requirement filed on October 12, 2006.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.

In response to the Restriction Requirement dated July 12, 2006 ("Restriction Requirement"), Applicants elect with traverse Group I (claims 2-6, 8, 11, and 19) for prosecution on the merits in the subject application. Applicants understand that claims 1 and 7, linking the isolated RNA compositions of elected claims 2-6 and 8, will be examined together with the linked claims.

Further, Applicants elect with traverse 5'-(U(C/U))₁₋₉(C/-)U₇₋₁₂C(C/-)-3' (SEQ ID NO:2) in claims 2 and 8, 5'-AGGUUAAGU-3' in claim 4, 5'-CCACAGC-3' in claim 5, and 5'-UACUAAC-3' in claim 6 for prosecution on the merits.